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Hyponatremia  often  associates  with  heart  failure.  Although  severe  salt  restriction  is generally  recom-
mended  in  heart  failure  treatment,  it may  promote  hyponatremia  which  is a risk  factor  for  increased
morbidity  and mortality  in  heart  failure  patients.  Therefore,  it  is  not  yet clear  whether  correction  of
hyponatremia  is  an  effective  treatment  in  congestive  heart  failure  with hyponatremia.  We experienced
a  successful  case  of  refractory  congestive  heart  failure  with  hyponatremia  treated  with  hypertonic  saline
and  furosemide.  A 45-year-old  man,  suffering  from  dilated  cardiomyopathy,  was  admitted  to  our hos-
pital  for  heart failure  worsening  with  hyponatremia.  We  started  diuretics  therapy  without  correction
of  hyponatremia,  but  his clinical  status  of  heart  failure  was  not  improved.  Therefore,  we  additionally
started  to correct  hyponatremia  by  continuous  injection  of  hypertonic  saline.  The  correction  of  hypona-
tremia  increased  urinary  volume  dramatically,  and  improved  cardiac  output  and  clinical  status  of  heart
failure.  This  case  strongly  suggests  that  combination  of  hypertonic  saline  and furosemide  could  enhance
diuretic  effect,  and improve  the  clinical  status  of  heart  failure  in  congestive  heart failure  patients  with
hyponatremia.
<Learning  objective:  Hyponatremia  is  a major  problem  associated  with  heart  failure,  but  it is  not  yet  clear
whether  correction  of hyponatremia  is an  effective  treatment  in  patients  with  congestive  heart  failure.
We  experienced  a successful  case  of  refractory  congestive  heart  failure  with  hyponatremia  treated  with
hypertonic  saline  and  low  dose  furosemide.  This  case  strongly  suggests  that  aggressive  correction  of
hyponatremia  can  be an effective  treatment  for refractory  congestive  heart  failure  with  hyponatremia.>
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ntroduction
Hyponatremia is a major problem associated with heart failure.
revious studies reported that hospital and post-discharge mortal-
ty were higher and hospital stay was longer in heart failure patients
ith hyponatremia than in those without hyponatremia [1]. How-
ver, there are no guidelines for the appropriate approach to treat
yponatremia associated with heart failure. We  describe a success-
ul case of refractory congestive heart failure with hyponatremia,
n which 40 mg  of furosemide and correction of hyponatremia with
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hypertonic saline increased urinary volume and cardiac output, and
improved the clinical status of heart failure.
Case report
A  45-year-old man  with general fatigue and dyspnea at rest
was admitted to our hospital in January 2013. He had been diag-
nosed with dilated cardiomyopathy after various examinations in
1993. His clinical status gradually got worse regardless of optimal
medical therapy including carvedilol, lisinopril, spironolactone,
furosemide, and amiodarone. He received cardiac resynchroniza-
tion therapy device implantation in September 2011, but his clinical
status was not improved and it continued to deteriorate. Eventually,
he was  hospitalized in our hospital in January 2013. His labora-
tory data showed 136 mEq/L of serum sodium, 1.8 mg/dL of serum
total bilirubin, 0.97 mg/dL of serum creatinine, and 2860 pg/mL of
vier Ltd. All rights reserved.
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(Table 1).
Therefore, we decided to correct hyponatremia aggressively.
We started continuous infusion of hypertonic saline (10% solu-
tion of sodium chloride, 46 mL/day) in addition to 40 mg  of
Table 1
Time  course of echocardiographic parameters, blood examination, and atrial blood
gas LVDd, left ventricular diastolic diameter; LVOT, velocity time integral at left ven-
tricular outﬂow tract; TR-PG, tricuspid regurgitation peak pressure gradient; AVP,
arginine vasopressin; BUN, serum blood urea nitrogen level; Cre, serum creatinine
level;  PaO2, partial pressure of oxygen in arterial blood; PaCO2, partial pressure
of  carbon dioxide in arterial blood. The combination therapy of hypertonic saline
with furosemide increased serum sodium level, not exponentially but gradually.
Additionally,  it did not lead to renal dysfunction and improved plasma AVP level.
Hospital day 1 31 38 45
Echocardiographic parameters
Ejection  fraction (%) 19 20 16 20
LVDd (mm)  78 76 75 77
LVOT-VTI (cm) 8.0 8.8 5.6 10.7
Stroke volume (mL) 27 30 19 36
TR-PG (mmHg) 52 41 34 43
Blood examination
AVP  (pg/mL) – – 12.7 3.6
BUN (mg/dL) 24 24 17 13
Cre (g/dL) 0.97 0.75 0.86 0.78
Serum sodium (mEq/L) 136 129 128 132
Arterial blood gas
F
d
w
o80 D. Morisawa et al. / Journal of
lasma B-type natriuretic peptide on admission. His body weight
as 78 kg on admission, which was a 5 kg gain compared with that
f the previous hospital discharge. Transthoracic echocardiography
howed an ejection fraction of 19%, left ventricular (LV) diastolic
iameter of 78 mm,  and velocity time integral at LV outﬂow tract
LVOT-VTI) of 8.0 cm.  These data suggested hypervolemic hypona-
remia, liver congestion, and low cardiac output due to right- and
eft-sided heart failure.
We  started continuous intravenous infusion of furosemide
0 mg/day, but that could not induce effective diuresis. There-
ore, we additionally started intravenous infusion of inotropes,
ow-dose dobutamine 3 g/kg/min, and that could induce effec-
ive diuresis. His body weight decreased to 71 kg about a week
fter the start of the therapy. However, serum sodium level and
rinary volume started to decrease gradually (Fig. 1). Despite
 kg of body weight loss, he was still presenting pulmonary
nd peripheral congestion about a month after the start of
he therapy. A hemodynamic study was performed on the 31st
ospital day, and it showed 18 mmHg  of mean right atrial pres-
ure, 38 mmHg  of mean pulmonary artery wedge pressure, and
.5 L/min/m2 of cardiac index. His laboratory data on the same
ay showed 129 mEq/L of serum sodium. Transthoracic echocar-
iography showed LVOT-VTI of 8.8 cm.  These data suggested
hat his clinical status was not improved and hyponatremia
as the cause. We  decided to introduce tolvaptan, vasopressin
ype 2 receptor antagonist, at 3.75 mg/day. One week after
he start of tolvaptan, urinary volume increased slightly and
ody weight reduced by 1.5 kg, but his symptoms of general
atigue and dyspnea were not improved (Fig. 1). His labora-
ory data on that day showed 128 mEq/L of serum sodium
nd 12.7 pg/mL of plasma arginine vasopressin (AVP) level, and
ig. 1. Time course of serum sodium level, urinary volume, body weight, and chest X-r
iuretics about one or two weeks after the start of the treatment. After the start of the com
eight  decreased. Serum sodium level was gradually improved. One week after the tolva
n  31st hospital day. One week after the start of the combination of hypertonic saline wilogy Cases 9 (2014) 179–182
his  echocardiography showed LVOT-VTI of 5.6 cm.  Despite the
administration of tolvaptan, his clinical status was not improvedPaO2 70 122 – 95
PaCO2 37 20 – 36
pH 7.382 7.554 – 7.422
Base excess −3.4 −5.5 – −1.5
ay. Serum sodium level was gradually decreasing, and became less responsive to
bination of hypertonic saline and furosemide, urinary volume increased and body
ptan, cardiothoracic ratio (CTR) of chest X-ray was increased, compared with that
th low-dose furosemide, the CTR was improved.
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wig. 2. Mechanism of hypertonic saline effects in congestive heart failure complicate
n  serum sodium level leads to an increase in cardiac output and a decrease in AVP
iuretics effect, and lead to an improvement in ﬂuid volume overload. AVP, arginin
urosemide. After that, urinary volume markedly increased and
ody weight decreased by 4.5 kg in a week. Serum sodium level
as improved (132 mEq/L) and plasma AVP level decreased dra-
atically (3.6 pg/mL) (Fig. 1 and Table 1). LVOT-VTI increased from
.6 cm to 10.7 cm in echocardiographic assessment. These data sug-
est that the combination therapy of furosemide and correction of
yponatremia with hypertonic saline enhanced diuretic effect, and
ncreased cardiac output.
Although cardiac output was improved, it was  difﬁcult to wean
notrope. Therefore, we  evaluated the status of his heart failure as
end-stage”, INTERMACS proﬁle 3: stable but inotrope dependent,
nd decided an indication of heart transplantation [2]. Eventually
e underwent the implantation of an artiﬁcial heart, EVAHEART®
Sun Medical, Nagano, Japan) with stable state in March 2013, for
he purpose of “bridge to transplantation”.
iscussion
Hyponatremia is a major problem associated with heart fail-
re, and no previous studies describe how to treat hyponatremia
n patients with heart failure. Salt restriction is believed to be an
ssential management of heart failure in clinical practice. The 2010
eart Failure Society of America guideline on acute decompensated
eart failure recommends a sodium intake of <2 g/day in patients
ith recurrent or refractory volume overload [3]. Most medical
roviders believe this management is applied in every status of
eart failure. However, some previous studies reported that severe
alt restriction increases neurohormonal activity, and reduces renal
lood ﬂow and glomerular ﬁltration rate [4,5]. Therefore, it is not
et clear whether aggressive correction of hyponatremia is an effec-
ive treatment in patients with congestive heart failure complicated
y hyponatremia.
Generally, cardiac output and effective blood circulation volume
re decreased in patients with severe congestive heart failure [6].
n such patients, non-osmotic stimulation of AVP is promoted via
aroreceptor signal, and an elevation of plasma AVP level leads to
ater retention, resulting in hypervolemic hyponatremia [7].
Hyponatremia  is also caused as a complication of heart failureherapy. Intravenous diuretics are administered to most patients
ospitalized for decompensated severe heart failure with volume
verload. Although intravenous diuretics are effective drugs for
ater excretion, they also facilitate excretion of sodium, result- hyponatremia. Hypertonic saline ﬁrstly increases serum sodium level. An increase
 through an increase in effective blood circulation volume. Those changes enhance
pressin.
ing  in hyponatremia [8]. Additionally, salt restriction which is
recommended in the guideline also promotes hyponatremia.
Therefore, hyponatremia can be caused by both diuretics and salt
restriction which are major therapies of heart failure [9].
Hyponatremia was reported as a risk factor for increased mor-
bidity and mortality in patients with chronic heart failure [1].
Therefore, aggressive correction of hyponatremia may  have favor-
able effects on heart failure complicated by hyponatremia. It may
increase cardiac output through an increase in effective blood
circulation volume, improve inappropriate elevation of AVP, and
enhance effects of diuretics (Fig. 2).
We actually administered 46 mL  of hypertonic saline (10% solu-
tion of sodium chloride) with 40 mg  of intravenous furosemide
in this case. This combination therapy of hypertonic saline with
low-dose furosemide dramatically increased the urinary volume
and decreased his body weight. Additionally, the LVOT-VTI, indi-
cator of cardiac output, was  dramatically improved. Hyponatremia
was gradually improved, and the plasma AVP level dramatically
decreased from 12.7 to 3.6 pg/mL.
Licata et al. previously reported that combination of hypertonic
saline and furosemide was useful therapy in heart failure [10]. How-
ever, an extremely high dose of furosemide (500–1000 mg) was
administered in the study, whereas the dose of furosemide was  only
40 mg  in our case. There is no report regarding the combination of
hypertonic saline and low-dose furosemide.
In conclusion, this case strongly suggests that the combination
therapy of hypertonic saline with low-dose furosemide is an effec-
tive treatment in patients with refractory congestive heart failure
complicated with hyponatremia.
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